Listed

Organon & Co.: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 3, 2023 and accepted by EDGAR at Nov 3, 2023, 07:52 ET.

Share

Management's discussion and analysis

As filed, 31,686 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general; an inability to fully execute on our product development and commercialization plans in the United States, Europe, and elsewhere internationally; an inability to adapt to the industry-wide trend toward highly discounted channels; changes in tax laws or other tax guidance which could adversely affect our cash tax liability, effective tax rates, and results of operations and lead to greater audit scrutiny; expanded brand and class competition in the markets in which Organon operates; global tensions, which may result in disruptions in the broader global economic environment; uncertainty regarding the U.S. federal budget and debt ceiling, and the impact of a potential U.S. federal government shutdown; governmental initiatives that adversely impact our marketing activities, particularly in China; volatility in Organon’s stock price; political and social pressures, or regulatory developments, that adversely impact demand for, availability of, or patient access to contraception or fertility products; difficulties with performance of third parties Organon relies on for its business growth; the failure of any supplier to provide substances, materials, or services as agreed; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties; competition from generic products as Organon's products lose patent protection; expiration of current patents or loss of patent protection for Organon's products; difficulties implementing or executing on Organon's acquisition strategy or failure to recognize the benefits of such acquisitions; and other factors discussed in Organon's most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

General

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to assist in understanding the Company’s financial condition and results of operations. The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and with our audited financial statements, including the accompanying notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022. Operating results discussed herein are not necessarily indicative of the results of any future period.

Organon & Co. ("Organon" or the "Company") is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

Recent Developments

Business Development

Claria Medical, Inc. ("Claria")

In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. Under the terms of the agreement, Organon paid $8 million upfront and has the option to acquire Claria for an additional $47 million, payable if and when the option is exercised. The $8 million was expensed as Acquired in-process research and development and milestones in our Condensed Consolidated Statement of Income for the nine months ended September 30, 2023.

COVID-19 Update

COVID-19 related disruptions, including patients' inability to access health care providers, prioritization of COVID-19 patients, as well as social distancing measures, negatively affected our results during 2022 and the first half of 2023, specifically, in China. During 2022 and to a lesser extent in the first half of 2023, our business was impacted by previous lockdowns in selective cities across China. The China economy has had a slower recovery post-COVID which has impacted the retail business.

Operating Results

Sales Overview

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
United States $370 $366 1% 1% $1,067 $1,043 2% 2%
International 1,149 1,171 (2) (1) 3,598 3,646 (1) 2
Total $1,519 $1,537 (1)% (1)% $4,665 $4,689 (1)% 2%

Worldwide sales were $1.5 billion for the three months ended September 30, 2023, a decrease of 1% compared with the same period in 2022. Worldwide sales were negatively impacted by approximately $10 million, due to unfavorable foreign exchange. Excluding foreign exchange, sales decreases primarily reflect Zetia® (ezetimibe) (marketed in most countries outside of the United States as Ezetrol™) and Vytorin® (ezetimibe/simvastatin) (marketed outside of the United States as Inegy™) driven by the impact of volume-based procurement ("VBP") in China, the Fertility portfolio mainly due to the negative impact of unfavorable discount rates in the United States, NuvaRing due to ongoing generic competition in the United States, Brenzys™ (etanercept) primarily driven by the timing of tenders in Brazil and Nexplanon due to unfavorable discount rates in the United States and decreased volume from the tender process in Mexico. This was offset by sales increases in Atozet™ (ezetimibe and atorvastatin calcium) (marketed outside of the United States) due to increased demand in France, Ontruzant driven by increased demand and the timing of tenders in Brazil and Renflexis driven primarily by continued demand growth in the United States and Canada.

Worldwide sales were $4.7 billion for the nine months ended September 30, 2023, consistent with 2022. Worldwide sales were negatively impacted by approximately 3%, or $119 million, due to unfavorable foreign exchange. Excluding foreign exchange, sales increases primarily reflect the performance of Atozet, due to increased demand in France and the timing of customers' buying patterns in the Middle East, Korea and Mexico, Renflexis driven primarily by continued demand growth in the United States and Canada, Arcoxia™ (etoricoxib) (marketed outside of the United States) primarily due to customers buying patterns in various international regions and higher demand in China, Jada due to continued uptake in the United States following the launch in February 2022, Dulera® (formoterol/fumarate dihydrate) primarily due to the favorable impact from discount rates and price in the United States and Marvelon™ (desogestrel and ethinyl estradiol pill) and Mercilon™ (desogestrel and ethinyl estradiol pill), resulting from the transaction with Bayer Healthcare where Organon gained full rights in selected territories in Southeast Asia and China during 2022. This performance was offset by Zetia and Vytorin driven by the impact of VBP in China, the impact of the Diprospan™ (betamethasone) regulatory inspection finding at the Heist manufacturing location that impacted the manufacturing of selected injectable steroid brands (the "Market Action") and decreased sales of Cozaar® (losartan potassium) and Hyzaar® (a combination of losartan potassium and hydrochlorothiazide that is marketed in Japan as Preminent™), primarily due to ongoing generic competition.

The loss of exclusivity negatively impacted sales by approximately $7 million and $9 million during the three and nine months ended September 30, 2023, compared to the three and nine months ended September 30, 2022, based on the decrease in volume period over period, mainly impacting NuvaRing in the United States. VBP in China had a $31 million and $83 million negative impact on sales during the three and nine months ended September 30, 2023, compared to the three and nine months ended September 30, 2022. Organon expects VBP to impact the Company's established brands product portfolio for the next several quarters.

Organon's operations include a portfolio of products. Highlights of the sales of Organon's products for the three and nine months ended September 30, 2023 and 2022 are provided below. See Note 5 "Product and Geographic Information" to the Condensed Consolidated Financial Statements for further details on sales of our products.

Women's Health

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
Nexplanon/Implanon NXT $220 $229 (4)% (3)% $599 $595 1% 2%
NuvaRing 37 50 (26) (23) 117 133 (12) (10)
Marvelon/Mercilon 30 31 (3) (2) 97 85 13 17
Follistim AQ 54 60 (10) (8) 179 179 — 3
Ganirelix Acetate Injection 25 36 (30) (29) 88 97 (9) (7)
Jada 13 5 134 134 31 12 150 150

Contraception

Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, decreased 4% for the three months ended September 30, 2023, compared to 2022 due to unfavorable discount rates in the United States and decreased volume from the tender process in Mexico. Sales of Nexplanon increased 1% for the nine months ended September 30, 2023, compared to 2022, primarily due to price increases, the impact of the timing of tenders in various international markets and the impact of distributors' buying patterns in prior periods in the United States, offset by unfavorable discount rates in the United States.

Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 26% and 12% for the three and nine months ended September 30, 2023, respectively, compared to 2022, due to ongoing generic competition in the United States. We expect a continued decline in NuvaRing sales as a result of generic competition.

Worldwide sales of Marvelon and Mercilon, combined oral hormonal daily contraceptive pills not approved or marketed in the United States but available in certain countries outside the United States, remained consistent for the three months ended September 30, 2023, compared to 2022. Sales of Marvelon and Mercilon increased 13% for the nine months ended September 30, 2023, compared to 2022, as a result of the transaction with Bayer Healthcare where Organon gained full rights in selected territories in Southeast Asia and China during 2022.

Fertility

Worldwide sales of Follistim AQ, a fertility treatment, declined 10% for the three months ended September 30, 2023, compared to 2022, due to the negative impact of unfavorable discount rates in the United States offset by increased demand. Sales of Follistim AQ remained consistent for the nine months ended September 30, 2023, compared to 2022, due to volume recovery in China related to the COVID-19 negative impact during the first half of the year, offset by the negative impact of unfavorable discount rates in the United States.

Worldwide sales of Ganirelix Acetate Injection (marketed in certain countries outside the United States as Orgalutran™), a fertility treatment, declined 30% and 9% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to unfavorable discount rates in the United States and the impact of distributors' buying patterns in several markets.

Other Women's Health

Worldwide sales of Jada, a device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, increased 134% and 150% for the three and nine months ended September 30, 2023, respectively, compared to 2022. The sales increase in both periods is due to continued uptake in the United States following the Jada launch.

Biosimilars

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
Renflexis $69 $60 15% 15% $201 $166 22% 22%
Ontruzant 40 29 36 34 93 87 8 7
Brenzys 13 24 (43) (41) 45 52 (13) (8)
Hadlima 8 6 38 42 20 14 48 55

Renflexis is a biosimilar to Remicade1 (infliximab) for the treatment of certain inflammatory diseases. Sales growth of 15% and 22% for the three and nine months ended September 30, 2023, respectively, compared to 2022, was driven primarily by continued demand growth in the United States and Canada. We have commercialization rights to Renflexis in countries outside Europe, Korea, China, Turkey, and Russia.

Ontruzant is a biosimilar to Herceptin1 (trastuzumab) for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Sales in the three and nine months ended September 30, 2023, compared to 2022, increased 36% and 8%, respectively, driven by increased demand and the timing of tenders in Brazil partially offset by the competitive pressures in Europe. We have commercialization rights to Ontruzant in countries outside of Korea and China.

Brenzys is a biosimilar to Enbrel1 (etanercept) for the treatment of certain inflammatory diseases. Sales in the three and nine months ended September 30, 2023, compared to 2022, declined 43% and 13%, respectively, primarily driven by the timing of tenders in Brazil. We have commercialization rights to Brenzys in countries outside of the United States, Europe, Korea, China, and Japan.

Hadlima is a biosimilar to Humira1 (adalimumab) for the treatment of certain inflammatory diseases. We have commercialization rights to Hadlima in countries outside of the EU, Korea, China, Turkey, and Russia. Hadlima is currently approved in the United States, Australia, Canada, and Israel. We recorded sales of $8 million and $20 million during the three and nine months ended September 30, 2023, respectively, reflecting an increase from modest sales during 2022 in markets outside of the United States and the launch in the United States in July 2023.

Established Brands

Established brands represents a broad portfolio of well-known brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies by market.

Cardiovascular

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
Zetia/Vytorin $99 $118 (16)% (16)% $339 $390 (13)% (11)%
Atozet 126 109 16 10 397 350 14 14
Cozaar/Hyzaar 68 70 (2) 2 225 256 (12) (7)

Combined global sales of Zetia and Vytorin, medicines for lowering LDL cholesterol, declined 16% and 13% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily driven by the impact of VBP in China.

Sales of Atozet, a medicine for lowering LDL cholesterol, increased 16% and 14% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to increased demand in France and the timing of customers' buying patterns in the Middle East, Korea, and Mexico.

Combined global sales of Cozaar and Hyzaar, medicines for the treatment of hypertension, declined 2% and 12% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to ongoing generic competition.

Respiratory

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
Singulair $91 $94 (4)% —% $290 $316 (8)% (3)%
Nasonex 55 49 10 16 188 182 3 7
Dulera 49 40 24 24 144 127 13 14

Worldwide sales of Singulair® (montelukast sodium), a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis, remained consistent during the three months ended September 30, 2023 compared to 2022. Sales of Singulair declined 8% during the nine months ended September 30, 2023, compared to 2022, due to increased pricing pressures in China related to renewal contracts for hospital tenders and the alleviation of our competitors' supply disruptions in Japan during 2022, which had positively impacted demand for Singulair in 2022.

Global sales of Nasonex® (mometasone), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 10% and 3% during the three and nine months ended September 30, 2023, compared to 2022, due to increased demand across several markets partially offset by a $10 million milestone payment related to a regulatory approval received during the first quarter of 2022.

Global sales of Dulera, a combination medicine for the treatment of asthma, increased 24% and 13% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to the favorable impact from discount rates and price in the United States.

Non-Opioid Pain, Bone and Dermatology

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
Arcoxia $64 $64 —% 5% $207 $185 12% 16%
Diprospan 31 28 10 11 58 91 (37) (36)

Sales of Arcoxia, a medicine for the treatment of arthritis and pain, remained consistent during the three months ended September 30, 2023 compared to 2022. Sales of Arcoxia increased 12% during the nine months ended September 30, 2023, compared to 2022, primarily due to customers buying patterns in various international regions and higher demand in China.

Sales of Diprospan, a corticosteroid approved for treatment of wide range of inflammatory conditions, increased 10% during the three months ended September 30, 2023 compared to 2022 as the Company replenishes supply from the Market Action. Sales of Diprospan declined 37% during the nine months ended September 30, 2023, compared to 2022, due to the Market Action. In the first quarter of 202

3, we resolved the regulatory inspection findings. The Company expects sales recovery to continue to occur over the next twelve months.

Other

($ in millions)

Three Months Ended September 30, 2023 2022 % Change % Change Excluding Foreign Exchange 2023 Nine Months Ended September 30, 2022 % Change % Change Excluding Foreign Exchange
Proscar $25 $27 (6)% (2)% $77 $77 —% 6%

Worldwide sales of Proscar, a medicine for the treatment of symptomatic benign prostate enlargement, for the three and nine months ended September 30, 2023 were substantially consistent with sales for the corresponding periods in 2022.

Costs, Expenses and Other

($ in millions)

Three Months Ended September 30, 2023 2022 % Change 2023 Nine Months Ended September 30, 2022 % Change
Cost of sales $612 $551 11% $1,832 $1,700 8%
Selling, general and administrative 538 440 22 1,424 1,234 15
Research and development 137 127 8 394 329 20
Acquired in-process research and development and milestones — 10 (100) 8 107 (93)
Restructuring costs — 11 (100) 4 11 (64)
Interest expense 134 108 24 398 303 31
Exchange losses (gains) 14 4 * 25 (21) *
Other expense, net 4 4 — 11 15 (27)
$1,439 $1,255 15% $4,096 $3,678 11%

* Calculation not meaningful.

Cost of Sales

Cost of sales increased 11% and 8% for the three and nine months ended September 30, 2023, respectively, compared to the same periods in 2022, primarily due to foreign exchange translation, higher employee-related costs and distribution related costs, which increased as a result of inflationary pressures, and product mix. During the nine months ended September 30, 2022, the Company recorded an impairment charge of $9 million related to a product right for a biosimilar product.

Selling, General and Administrative

Selling, general and administrative expenses increased 22% and 15% for the three and nine months ended September 30, 2023, respectively, compared to the same period in 2022, due to higher employee-related costs, costs incurred in connection with the separation from Merck, which includes the implementation of the enterprise resource planning system, and the $80 million charge related to the Microspherix legal matter as discussed in Note 15. "Contingencies" to the Condensed Consolidated Financial Statements.

Research and Development

Research and development expenses increased 8% and 20% for the three and nine months ended September 30, 2023, respectively, compared to the same period in 2022, primarily due to higher costs associated with the Company's recent acquisitions of clinical stage assets, increased clinical study activity and higher employee-related costs.

Acquired In-Process Research and Development and Milestones

For the nine months ended September 30, 2023, acquired in-process research and development and milestones of $8 million related to the Claria transaction. For the three months ended September 30, 2022, acquired in-process research and development and milestones represents the upfront milestones related to the Cirqle transaction. For the nine months ended September 30, 2022 acquired in-process research and development and milestones represents the upfront and development milestones related to both the Cirqle and Henlius transactions.

Restructuring Costs

For the nine months ended September 30, 2023, the Company incurred $4 million of headcount related restructuring expense as part of the restructuring activities which were initiated during 2022 to optimize its internal operations.

Interest Expense

For the three months ended September 30, 2023, interest expense increased due to increased interest rates on our term loans. For the nine months ended September 30, 2023, interest expense increased due to increased interest rates, unamortized debt fees and discounts expensed as part of the prepayment on the U.S. Dollar-denominated term loan and the impact of exchange rates.

Exchange Losses (Gains)

For the three and nine months ended September 30, 2023, the change in exchanges losses (gains) was driven by foreign currency translation losses as well as the impact of the portion of Euro-denominated debt not designated as a net investment hedge in the prior year period.

Other Expense, net

For the three and nine months ended September 30, 2023, other expense, net, remained relatively consistent with the prior year.

Taxes on Income

The effective income tax rates were 27.0% and 19.6% for the three months ended September 30, 2023 and 2022, respectively, and 16.1% and 20.0% for the nine months ended September 30, 2023 and 2022, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. The 2023 quarter-to-date and year-to-date effective tax rate favorable impact is primarily attributable to a reduced tax rate arrangement that was agreed to in Switzerland for an active entity.

On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2023 results. The Company will continue to assess future impacts of this legislation.

Liquidity and Capital Resources

As of September 30, 2023, Organon had cash and cash equivalents of $414 million.

Working capital was $1.6 billion and $1.4 billion as of September 30, 2023 and December 31, 2022, respectively. The increase in working capital was primarily driven by an increase in inventory and the timing of collection of receivables.

Net cash provided by operating activities was $402 million for the nine months ended September 30, 2023 compared to $591 million for the same period in the prior year. The decrease in cash provided by operating activities was primarily attributable to lower net income partially offset by the changes in working capital balances.

Net cash used in investing activities was $179 million for the nine months ended September 30, 2023 compared to $359 million for the same period in the prior year, primarily reflecting lower investment in business development transactions in the nine months ended September 30, 2023 compared to the same period in the prior year, partially offset by an increase in capital expenditures.

Net cash used in financing activities was $492 million for the nine months ended September 30, 2023 compared to $351 million for the same period in the prior year. The increase in cash used in financing activities was driven by the $250 million voluntary prepayment on the U.S. Dollar-denominated term loan in the first quarter of 2023.

Organon will continue to monitor the impacts of the Ukraine-Russia war and the Hamas-Israel war, which may negatively impact Organon's operations, financial position, or cash flows. For the three and nine months ended September 30, 2023 and 2022, Organon's combined revenues from Ukraine, Russia and Israel were approximately 2% of total revenues. As of September 30, 2023, the Company's assets in Ukraine, Russia and Israel are not material.

Our contractual obligations as of September 30, 2023, which require material cash requirements in the future, consist of contractual milestones, purchase obligations and lease obligations. In addition, Organon is responsible for settlement of certain tax matters that the Company expects to pay during 2023. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2022 for further details. The Company has terminated the ebopiprant license agreement and development program; as a result, the Company will not owe the previously disclosed $25 million milestone payment or other milestone payments under the ebopiprant license agreement. As of September 30, 2023, there have been no material changes to our contractual obligations, or settlements of tax matters outside the ordinary course of business.

During the third quarter of 2023, Organon paid cash dividends of $0.28 per share. On November 2, 2023, the Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 14, 2023, to stockholders of record at the close of business on November 13, 2023.

The Company has historically generated and expects to continue to generate positive cash flow from operations. Our ability to fund our operations and anticipated capital needs is reliant upon the generation of cash from operations, supplemented as necessary by periodic utilization of our Revolving Credit Facility. Our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures, repayment of borrowings, payment of dividends and strategic business development transactions. We believe that our financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund our future cash flow needs.

Critical Accounting Estimates

Our significant accounting policies, which include management’s best estimates and judgments, are included in Note 3 "Summary of Accounting Policies" to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. See Note 2 "Basis of Presentation" to the Condensed Consolidated Financial Statements for information on the adoption of new accounting standards during 2023. There have been no changes to our accounting policies as of September 30, 2023. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022.

Recently Issued Accounting Standards

For a discussion of recently issued accounting standards, see Note 2 "Basis of Presentation" to the Condensed Consolidated Financial Statements.

Market risk

As filed, 1,387 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Foreign Currency Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely affected by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to forecasted transactions and net assets denominated in the euro, Swiss franc, and Japanese yen. We established a balance sheet risk management program and a net investment hedge to mitigate against volatility of changes in foreign exchange rates. See Note 10 "Financial Instruments" to the Condensed Consolidated Financial Statements included elsewhere in this report for further information on Organon’s risk management.

Interest Rate Risk

Our long-term debt portfolio consists of both fixed and variable-rate instruments. For any variable rate debt, interest rate changes in the underlying index rates will impact future interest expense. We do not hold any derivative contracts that hedge our interest rate risk; however, we may consider entering into such contracts in the future.

There have been no changes to Organon’s market risk during the quarter ended September 30, 2023. For a discussion of our exposure to market risk, refer to our market risk disclosures set forth under Item 7A.—Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2022.

Controls and procedures

As filed, 1,954 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Management of the Company, with the participation of its Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the period ending September 30, 2023. Based upon that evaluation, our CEO and our CFO concluded that, as of September 30, 2023, the end of the period covered by this report, the Company's disclosure controls and procedures were effective and provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including our CEO and our CFO, as appropriate, to allow timely decisions regarding required disclosure.

The Company began an implementation of an enterprise resource planning ("ERP") system, which will replace the existing core financial system. The ERP system is designed to accurately maintain the Company's financial records used to report operating results. The implementation of the consolidated financial reporting module will be completed during Q4 of the 2023 fiscal year. The implementation of the general ledger modules is in progress and occurring in phases and is expected to be completed by the first half of 2024. The changes in process under the new ERP will continue to be subject to our evaluation of the operating effectiveness of internal control over financial reporting.

Except for the implementation of an ERP system, there was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 254 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in the Company's risk factors from those disclosed in Item 1A. Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-07-01 to 2023-09-30$1.52bnus-gaap:Revenues
Revenue9 months2023-01-01 to 2023-09-30$4.67bnus-gaap:Revenues
Cost of revenue3 months2023-07-01 to 2023-09-30$612.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2023-01-01 to 2023-09-30$1.83bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2023-07-01 to 2023-09-30$538.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2023-01-01 to 2023-09-30$1.42bnus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2023-07-01 to 2023-09-30$134.0mus-gaap:InterestExpense
Interest expense9 months2023-01-01 to 2023-09-30$398.0mus-gaap:InterestExpense
Income tax3 months2023-07-01 to 2023-09-30$22.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2023-01-01 to 2023-09-30$92.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-01 to 2023-09-30$58.0mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30$477.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30$0.23us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30$1.86us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30$0.23us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30$1.87us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-30256,349,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-30256,162,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30$402.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2023-01-01 to 2023-09-30$172.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2023-01-01 to 2023-09-30$221.0mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2023-09-30$414.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$4.05bnus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$11.01bnus-gaap:Assets
Current liabilitiesAt period end2023-09-30$2.49bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$11.60bnus-gaap:Liabilities
Long-term debtAt period end2023-09-30$8.65bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-09-30$8.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-09-30−$589.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001821825-23-000013. Last ingested by Listed: Nov 11, 2026, 00:27 ET. Listed shows no prices and gives no investment advice.